Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 15, 2017
|Conference Call & Webcast|
|Wednesday, November 15 @ 8:30am Eastern Time|
|Replays, Available through November 29:|
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Our clinical stage product candidates include our novel minocycline foam FMX101 for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including
For more information, please visit www.foamixpharma.com.
|Contact:||US Investor Relations|
|Ilan Hadar, CFO & Country Manager||Michael Rice|
|Foamix Pharmaceuticals Ltd.||LifeSci Advisors, LLC|
Source: Foamix, Ltd.